Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.

Naiditch H, Shurin MR, Shurin GV.

Immunol Res. 2011 Aug;50(2-3):276-85. doi: 10.1007/s12026-011-8213-2.

PMID:
21717082
[PubMed - indexed for MEDLINE]
2.

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.

Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I.

J Exp Med. 2006 Nov 27;203(12):2691-702. Epub 2006 Nov 13.

PMID:
17101732
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Myeloid-derived suppressor cells--their role in haemato-oncological malignancies and other cancers and possible implications for therapy.

Tadmor T, Attias D, Polliack A.

Br J Haematol. 2011 Jun;153(5):557-67. doi: 10.1111/j.1365-2141.2011.08678.x. Epub 2011 Apr 8. Review.

PMID:
21477210
[PubMed - indexed for MEDLINE]
4.

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.

Michels T, Shurin GV, Naiditch H, Sevko A, Umansky V, Shurin MR.

J Immunotoxicol. 2012 Jul-Sep;9(3):292-300. doi: 10.3109/1547691X.2011.642418. Epub 2012 Jan 28.

PMID:
22283566
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Chemotherapeutic targeting of cancer-induced immunosuppressive cells.

Alizadeh D, Larmonier N.

Cancer Res. 2014 May 15;74(10):2663-8. doi: 10.1158/0008-5472.CAN-14-0301. Epub 2014 Apr 28. Review.

PMID:
24778417
[PubMed - indexed for MEDLINE]
6.

Tumor-induced immune dysfunctions caused by myeloid suppressor cells.

Bronte V, Serafini P, Apolloni E, Zanovello P.

J Immunother. 2001 Nov-Dec;24(6):431-46. Review.

PMID:
11759067
[PubMed - indexed for MEDLINE]
7.

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer.

Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI.

J Immunol. 2001 Jan 1;166(1):678-89.

PMID:
11123353
[PubMed - indexed for MEDLINE]
Free Article
8.

Cross-talk between tumor and myeloid cells: how to tip the balance in favor of antitumor immunity.

Lindenberg JJ, Fehres CM, van Cruijsen H, Oosterhoff D, de Gruijl TD.

Immunotherapy. 2011 Jan;3(1):77-96. doi: 10.2217/imt.10.95. Review.

PMID:
21174559
[PubMed - indexed for MEDLINE]
9.

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Albeituni SH, Ding C, Yan J.

Cancer J. 2013 Nov-Dec;19(6):490-501. doi: 10.1097/PPO.0000000000000006. Review.

PMID:
24270348
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients.

Filipazzi P, Huber V, Rivoltini L.

Cancer Immunol Immunother. 2012 Feb;61(2):255-63. doi: 10.1007/s00262-011-1161-9. Epub 2011 Nov 27. Review.

PMID:
22120756
[PubMed - indexed for MEDLINE]
11.

Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells.

Jinushi M, Yagita H, Yoshiyama H, Tahara H.

Trends Mol Med. 2013 Sep;19(9):536-45. doi: 10.1016/j.molmed.2013.06.001. Epub 2013 Jun 27. Review.

PMID:
23810190
[PubMed - indexed for MEDLINE]
12.

Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions.

Bronte V.

Eur J Immunol. 2009 Oct;39(10):2670-2. doi: 10.1002/eji.200939892.

PMID:
19757440
[PubMed - indexed for MEDLINE]
13.

Advances in understanding regulatory myeloid cells.

Romano A, Vetro C, Adriani M.

Cancer Biol Ther. 2011 Jun 1;11(11):923-6. Epub 2011 Jun 1.

PMID:
21474999
[PubMed - indexed for MEDLINE]
Free Article
14.

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

Kao J, Ko EC, Eisenstein S, Sikora AG, Fu S, Chen SH.

Crit Rev Oncol Hematol. 2011 Jan;77(1):12-9. doi: 10.1016/j.critrevonc.2010.02.004. Epub 2010 Mar 20. Review.

PMID:
20304669
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Role of myeloid-derived suppressor cells in tumor immunotherapy.

Martin F, Apetoh L, Ghiringhelli F.

Immunotherapy. 2012 Jan;4(1):43-57. doi: 10.2217/imt.11.154. Review.

PMID:
22150000
[PubMed - indexed for MEDLINE]
16.

Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms.

Lizée G, Radvanyi LG, Overwijk WW, Hwu P.

Clin Cancer Res. 2006 Aug 15;12(16):4794-803. Review.

PMID:
16914564
[PubMed - indexed for MEDLINE]
Free Article
17.

Polysaccharide from Lentinus edodes inhibits the immunosuppressive function of myeloid-derived suppressor cells.

Wu H, Tao N, Liu X, Li X, Tang J, Ma C, Xu X, Shao H, Hou B, Wang H, Qin Z.

PLoS One. 2012;7(12):e51751. doi: 10.1371/journal.pone.0051751. Epub 2012 Dec 18.

PMID:
23272159
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Myeloid-derived suppressor cells: a novel therapeutic target.

Ko JS, Bukowski RM, Fincke JH.

Curr Oncol Rep. 2009 Mar;11(2):87-93. Review.

PMID:
19216839
[PubMed - indexed for MEDLINE]
19.

Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells.

Hackstein H, Morelli AE, Larregina AT, Ganster RW, Papworth GD, Logar AJ, Watkins SC, Falo LD, Thomson AW.

J Immunol. 2001 Jun 15;166(12):7053-62.

PMID:
11390449
[PubMed - indexed for MEDLINE]
Free Article
20.

Molecular pathways: tumor-infiltrating myeloid cells and reactive oxygen species in regulation of tumor microenvironment.

Lu T, Gabrilovich DI.

Clin Cancer Res. 2012 Sep 15;18(18):4877-82. doi: 10.1158/1078-0432.CCR-11-2939. Epub 2012 Jun 19. Review.

PMID:
22718858
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk